Positive MS data may thwart Icahn’s plans for Genzyme

Follow-up data from a Phase II trial of Campath (alemtuzumab) for multiple sclerosis revealed that about 71 percent of patients remain free the disease for up to three years after receiving their last dose of the drug. The study compared Campath to the Merck KGaA's approved MS therapy Rebif in early, active, relapsing-remitting multiple sclerosis patients who had received no prior therapy. Genzyme presented the positive data at the American Academy of Neurology annual...